source
- Analysts say Daiichi Sankyo’s ADC pipeline lags rivals as cash flow peaks, cutting expectationsJefferies analysts warned that Daiichi Sankyo's early‑stage antibody‑drug conjugate (ADC) pipeline is falling behind competitors, even as the company approaches a peak in cash flow from its existin…
- FDA advisory panel backs Replimune’s melanoma immunotherapy combined with OpdivoThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10-3 to recommend Replimune’s RP1 immunotherapy, used together with Bristol Myers Squibb’s Opdivo, for patients with advanced…